Further to the announcement made on 13 September 2018, Scapa Group plc (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018. In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.
Back to All News
All Market News
Other Market News
Alliance Witan plc – Final Results
AstraZeneca Releases Imfinzi Update
Smithson Investment Trust Annual Financial Report
Segro plc Announces Selp’s Completion of Assets Purchase
F.W. Thorpe – Interim Results
Murray International Trust – Annual Financial Report
Sign up for our Stock News Highlights
Delivered to your inbox every Friday